Rüfer Axel, Müllner Gerhard, Fuchs Oliver, Sperr Wolfgang R, Hoermann Gregor
Department of Hematology, Centre of Excellence of the European Competence Network on Mastocytosis (ECNM), Luzerner Kantonsspital, Lucerne, and University of Lucerne, Lucerne, Switzerland.
Allergology and Immunology, Medbase Kriens Mattenhof, Kriens, Switzerland.
Swiss Med Wkly. 2025 Apr 2;155:3679. doi: 10.57187/s.3679.
Hereditary alpha-tryptasemia (HAT) is an autosomal dominant genetic trait affecting 4% to 6% of the general population. Hereditary alpha-tryptasemia is caused by an excess of alpha tryptase encoding TPSAB1 copy numbers on one parenteral allele, most often duplications or triplications, leading to elevated levels of basal serum tryptase. There might be a gene dosage effect between the number of additional TPSAB1 copies, the level of basal serum tryptase and the severity of clinical symptoms, including atopic, cutaneous, gastrointestinal, musculoskeletal, autonomic and neuropsychiatric manifestations. Hereditary alpha-tryptasemia is a potential risk factor for severe anaphylactic reactions. The prevalence of hereditary alpha-tryptasemia is higher in patients with systemic mastocytosis. In the diagnostic workup of patients with anaphylactic reactions and symptoms of mast cell mediator release after measurement of basal serum tryptase, it is therefore essential to screen for both the KIT D816V activating point mutation and hereditary alpha-tryptasemia by droplet digital polymerase chain reaction. Such a diagnostic approach can identify patients with hereditary alpha-tryptasemia, which may allow the avoidance of further diagnostic workup with bone marrow examination. Moreover, it can identify patients at high risk of anaphylactic reactions. So far, no targeted therapy for hereditary alpha-tryptasemia is available. Treatment for symptom control consists of H1- and H2-blockers, leukotriene antagonists and cromoglicic acid. Urticaria and anaphylaxis are especially successfully treated with the monoclonal anti-IgE-antibody omalizumab in patients with hereditary alpha-tryptasemia. H1-blockers and steroids are sufficient in emergencies. As hereditary alpha-tryptasemia is a hereditary condition, first-degree relatives with anaphylactic reactions or symptoms of mast cell mediator release should be tested for hereditary alpha-tryptasemia after measurement of basal serum tryptase.
遗传性α-色氨酸血症(HAT)是一种常染色体显性遗传性状,影响着4%至6%的普通人群。遗传性α-色氨酸血症是由一个亲代等位基因上编码TPSAB1的α-色氨酸酶拷贝数过多引起的,最常见的是重复或三倍体,导致基础血清色氨酸酶水平升高。额外的TPSAB1拷贝数、基础血清色氨酸酶水平与临床症状的严重程度之间可能存在基因剂量效应,临床症状包括特应性、皮肤、胃肠道、肌肉骨骼、自主神经和神经精神表现。遗传性α-色氨酸血症是严重过敏反应的潜在危险因素。系统性肥大细胞增多症患者中遗传性α-色氨酸血症的患病率更高。因此,在测量基础血清色氨酸酶后,对有过敏反应和肥大细胞介质释放症状的患者进行诊断检查时,通过液滴数字聚合酶链反应筛查KIT D816V激活点突变和遗传性α-色氨酸血症至关重要。这种诊断方法可以识别遗传性α-色氨酸血症患者,从而避免进一步进行骨髓检查的诊断工作。此外,它还可以识别过敏反应高危患者。到目前为止,尚无针对遗传性α-色氨酸血症的靶向治疗方法。症状控制治疗包括H1和H2阻滞剂、白三烯拮抗剂和色甘酸。遗传性α-色氨酸血症患者使用单克隆抗IgE抗体奥马珠单抗治疗荨麻疹和过敏反应特别有效。在紧急情况下,H1阻滞剂和类固醇就足够了。由于遗传性α-色氨酸血症是一种遗传性疾病,有过敏反应或肥大细胞介质释放症状的一级亲属在测量基础血清色氨酸酶后应检测遗传性α-色氨酸血症。